Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, TD Cowen Analyst Says

Gilead Sciences (NASDAQ:GILD) had its price objective raised by equities research analysts at TD Cowen from $125.00 to $145.00 in a research report issued to clients and investors on Thursday,MarketScreener reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. TD Cowen’s price objective would indicate a potential upside of 2.15% from the stock’s current price.

GILD has been the topic of several other reports. Royal Bank Of Canada increased their target price on Gilead Sciences from $100.00 to $103.00 and gave the stock a “sector perform” rating in a report on Tuesday, January 20th. Citigroup increased their price objective on shares of Gilead Sciences from $140.00 to $156.00 and gave the stock a “buy” rating in a research note on Tuesday. Needham & Company LLC raised their target price on shares of Gilead Sciences from $133.00 to $140.00 and gave the company a “buy” rating in a report on Thursday, November 13th. The Goldman Sachs Group boosted their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a research report on Thursday, January 8th. Finally, Rothschild & Co Redburn increased their price target on shares of Gilead Sciences from $153.00 to $159.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average price target of $136.36.

Gilead Sciences Stock Up 1.7%

Shares of GILD opened at $141.95 on Thursday. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. Gilead Sciences has a 12 month low of $93.37 and a 12 month high of $142.20. The firm’s 50 day moving average is $125.36 and its 200-day moving average is $119.59. The stock has a market capitalization of $176.11 billion, a PE ratio of 22.01, a P/E/G ratio of 0.73 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period in the previous year, the company posted $2.02 earnings per share. Equities research analysts forecast that Gilead Sciences will post 7.95 EPS for the current year.

Insider Activity

In related news, Director Kelly A. Kramer sold 2,805 shares of Gilead Sciences stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $127.10, for a total transaction of $356,515.50. Following the sale, the director directly owned 1,339 shares in the company, valued at $170,186.90. This trade represents a 67.69% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the sale, the insider directly owned 103,221 shares in the company, valued at $12,831,402.51. The trade was a 2.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 257,397 shares of company stock valued at $33,385,512. 0.27% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Gilead Sciences

A number of hedge funds have recently modified their holdings of the business. GoalVest Advisory LLC raised its position in Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the last quarter. Corundum Trust Company INC acquired a new stake in shares of Gilead Sciences in the third quarter valued at about $26,000. Harbor Asset Planning Inc. bought a new position in shares of Gilead Sciences during the second quarter worth about $27,000. Ares Financial Consulting LLC bought a new position in shares of Gilead Sciences during the fourth quarter worth about $28,000. Finally, Financial Consulate Inc. lifted its stake in shares of Gilead Sciences by 85.8% in the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 109 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Multiple sell‑side firms raised targets and reiterated bullish ratings (Wolfe Research to $155/outperform; TD Cowen to $145/buy), reinforcing buy-side momentum and implied upside from current levels. Read More. Read More.
• Positive Sentiment: Broader analyst upgrades/positive notes from Citi, Truist, BMO and UBS add to consensus bullishness, supporting demand and higher valuation multiples. Read More.
• Positive Sentiment: Clinical/regulatory wins for Trodelvy (added to NCCN guidelines; TNBC approval/win coverage) strengthen Gilead’s oncology growth story and revenue optionality beyond antivirals. Read More. Read More.
• Positive Sentiment: Coverage pieces noting that GILD has outperformed the market and is attracting analyst attention can draw momentum and ETF/quant flows into the stock. Read More.
• Neutral Sentiment: Notes on GILD’s presence in Nasdaq/healthcare ETF lineups and elevated investor attention increase volume and liquidity but are not clear directional catalysts by themselves. Read More.
• Negative Sentiment: Insider selling: CEO Daniel Patrick O’Day sold 10,000 shares (~$1.4M) at ~$139.89 (filed on Form 4). While modest relative to his remaining holding and potentially routine, insider sales can be interpreted negatively by some investors. Read More.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.